2025-05-02 11:26:18
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients
Posted On : 2023-01-18 15:18:30( TIMEZONE : IST )
Global pharma major Lupin Limited (Lupin) today announced the launch of combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg.
In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure and the estimated prevalence ranges from 1.3 to 4.6 million. In addition, the HF pattern in India is considered different from the rest of the world due to factors such as the average age of Indian patients with HF being 10 years younger than the global average, the high prevalence of hypertension and diabetes, and limited adoption of guideline-directed medical therapy, among others. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.
Commenting on the launch, Rajeev Sibal, President - India Region Formulations, Lupin said, "Heart failure is a difficult condition with severe unmet needs, necessitating the development of treatment agents to improve patient outcomes. As a leader in the cardiac therapy area, Lupin is committed to offer patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need, while reducing the cost of therapy."
Shares of Lupin Limited was last trading in BSE at Rs. 753.05 as compared to the previous close of Rs. 756.80. The total number of shares traded during the day was 6618 in over 806 trades.
The stock hit an intraday high of Rs. 756.40 and intraday low of 745.15. The net turnover during the day was Rs. 4974251.00.
